Nova TheraNostics (NTN) is developing a new and uniquely differentiated contrast agent for use with magnetic resonance imaging (MRI) that will not only be highly competitive relative to existing agents, but will also enable the extension of MRI into new indications not currently served by this imaging modality. NTNís contrast agent, Nanobriteô, will be the only gadolinium-based contrast agent (GBCA) capable of serving some of these new MRI diagnostic indications, garnering for itself a large, new, captive market in addition to significant penetration of the existing GBCA market.
NTNís Nanobrite is fundamentally different than existing GBCAs in four key attributes: first, the agentís contrast brightness is up to an order of magnitude greater than existing agents; second, the agentís useful imaging window is an order of magnitude longer than that of all existing agents; third, the agent is rigorously intravascular, virtually eliminating the interstitial escape that degrades signal/noise contrast and increases the risk of toxicity; and, fourth, its clearance is uniquely and predominantly through the hepatobiliary pathway, avoiding the substantial limitations and risks associated with all other agentsí renal clearance.
Nova TheraNostics Brightens MRI Images (case study)By Eran Moore Rea
It was a surprise. Dr. Rodney Ho, UW professor of pharmaceutics, researches drug delivery for HIV treatment. In 2009, he created a new way to deliver HIV drugs to patients. HIV drugs rarely make it effectively to a patientís lymph nodes. Ho thought binding the drugs to lipid (fatty particle) nanoparticles might help drug delivery. Read More
University of Washington launches a record 17 start-up companies in FY13; places UW with top five universities for commercializationJuly 18, 2013
The University of Washington launched 17 new start-up companies in the past fiscal year based on UW research technologies, making FY 13 the UWís single most productive year for start-up formation, and placing the UW among the top five schools in the nation for commercialization efforts, along with MIT, the University of Illinois, the University of Utah, UCLA and Columbia University. Read More